Buer J, Kirchner H, Schomburg A, Schüler A, Manns M, Lopez-Hänninen E, Duensing S, Poliwoda H, Atzpodien J
Abteilung Hämatologie und Onkologie, Medizinische Hochschule Hannover, Germany.
Clin Investig. 1994 Jul;72(7):526-34. doi: 10.1007/BF00207483.
Over the past 20 years the administration of cytokines has emerged as an important fourth modality for the treatment of human cancer. Advances in the field of therapy of gastrointestinal tumors have become a major focus of current research, given the lack of progress of conventional antineoplastic therapy in most of these tumors. Among the heterogeneous group of gastrointestinal malignancies, novel therapeutic strategies have been employed for each individual tumor type, and cytokines (interferon-alpha) have gained an established role in the treatment of advanced carcinoid tumors. Although our understanding of the mechanisms of biological response modification is still limited, further improvement in the management of gastrointestinal malignancies can be expected from multimodality therapy regimens employing cytokines in combination with other biological response modifiers, chemotherapeutic agents, active-specific immunotherapy, and immunotoxin- and radionuclide-conjugated monoclonal antibodies. A wide range of clinical and preclinical studies have been conducted in colorectal carcinoma; however, potential therapeutic benefit of cytokine-based biotherapy has not been fully defined. Therefore, largescale, i.e., multicenter, studies are required to quantify the potential therapeutic effects of cytokines in gastrointestinal tumors.
在过去20年中，细胞因子的应用已成为治疗人类癌症的重要第四种方式。鉴于大多数胃肠道肿瘤的传统抗肿瘤治疗进展甚微，胃肠道肿瘤治疗领域的进展已成为当前研究的主要焦点。在胃肠道恶性肿瘤这一异质性群体中，针对每种肿瘤类型都采用了新的治疗策略，而细胞因子（α干扰素）在晚期类癌肿瘤的治疗中已确立了其作用。尽管我们对生物反应修饰机制的理解仍然有限，但采用细胞因子与其他生物反应调节剂、化疗药物、主动特异性免疫疗法以及免疫毒素和放射性核素偶联单克隆抗体联合使用的多模式治疗方案有望进一步改善胃肠道恶性肿瘤的治疗。在结直肠癌方面已经进行了广泛的临床和临床前研究；然而，基于细胞因子的生物疗法的潜在治疗益处尚未完全明确。因此，需要进行大规模的，即多中心的研究，以量化细胞因子在胃肠道肿瘤中的潜在治疗效果。
